All
First patient dosed in phase I/IIa clinical trial of ABI-110
ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.
Flagship dataset released to better understand type 2 diabetes development
Study participants include people with no diabetes as well as those with various stages of the condition, creating a set of information distinct from previous research.
Sunil Gupta, MD, joins the Nanoscope Therapeutics Inc.’s Board of Directors
Gupta is a nationally recognized retinal surgeon and an entrepreneur whose knowledge and experience on the phases of drug development and medical devices.
NIH announces elements of brain-based visual impairment in children
Research needed to establish best diagnostic and management strategies for increasingly common condition.
The FDA extends the PDUFA for the biologics license application of NT-501
The new PDUFA goal date for NT-501 as treatment for macular telangiectasia type 2 (MacTel) is March 18, 2025.
Harrow to reduce prices and partner with GoodRx
Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products.
Adverum Biotechnologies shares positive 52-week LUNA and 4-year OPTIC results
LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human trial.
Opthea to present at upcoming events to highlight work on wet AMD
Gregg T. Kokame, MD, MMM, FASRS, is set to share data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks.
Arctic Vision signs a new commercial collaboration agreement with Santen Pharmaceutical Co., Ltd. for ARVN001
ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development.
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy
Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option.
Excellence across the board at the 2024 Euretina Congress
This year’s Barcelona meeting brought together award-winning research findings and leaders in the retina field.
Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease
The designations underscore the unmet need in Stargardt disease, a rare and serious pediatric disease for which no treatment exists.
The CHMP issues positive opinion for the marketing authorization of FYB203
FYB203 has been recommended by the CHMP for approval in Europe for treating adult patients with age-related neovascular macular degeneration (nAMD) and other serious retinal diseases.
US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY)
The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.
A-memia? Anecdotal evidence in the era of memes
Ian C. Han, MD, shares his thoughts on the value of anecdotal evidence in our winter 2024 editorial.
NHS introduces OCT program to reduce annual hospital visits for patients with diabetes
Optical coherence tomography will be in all eye care services by October 2025
AlloVir, Inc. enters definitive merger agreement to combine with Kalaris Therapeutics
The European Commission approves biosimilar referencing aflibercept by Samsung Bioepis
The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15.
New treatment options provide effective management of geographic atrophy
In a recent Modern Retina case-based discussion, Ferhina S. Ali, MD, MPH, discussed how to effectively manage geographic atrophy (GA).
Ocular nerve regrowth following use of diabetes drug
A case report demonstrates independent effect of GLP-1 receptor agonist.
Merger of Akari Therapeutics, Plc and Peak Bio, Inc. is complete
This merger creates an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies.
The deep dish on all things ophthalmology at AAO 2024
The annual meeting, held in Chicago, Illinois, featured new data and best practices for patient-centered care.
Boehringer Ingelheim joins the Mary Tyler Moore Vision Initiative to combat vision loss from diabetes
This announcement establishes Boehringer as the first pharmaceutical company to join the MTM Vision Consortium.
European Commission grants marketing authorization to biosimilar from Sandoz Group
Afqlir (aflibercept) is a 2 mg vial kit and pre-filled syringe for intravitreal injection.
Identifying and monitoring GA: Technologic improvements over time
Srinivas R. Sadda, MD, described the advantages and disadvantages of the various imaging technologies used to evaluate GA at the AAO 2024 conference.
Wet AMD therapeutics: Technologies raising the ceiling for functional visual outcomes
Neovascular macular degeneration is multifactorial, which requires future agents to target multiple pathways.
Advancements in ocular drug delivery
Options empower patients and providers to decrease treatment burden
A field guide to optic disc drusen
Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.
New data on PST-611 from PulseSight Therapeutics SAS shared at EVER Congress 2024
PST-611 is a first in class non-viral vectorized therapy for the treatment of dry AMD/GA coding for human transferrin.
Cencora to acquire Retina Consultants of America for up to $5.1 Billion
The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora.
